Global Peptide Cancer Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2020-2026
Table of Contents1 Study Coverage
1.1 Peptide Cancer Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Type
1.2.2 Type I
1.2.3 Type II
1.3 Market by Application
1.3.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Application
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Melanoma
1.3.5 Prostate Cancer
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Peptide Cancer Vaccine Market Size Estimates and Forecasts
2.1.1 Global Peptide Cancer Vaccine Revenue 2015-2026
2.1.2 Global Peptide Cancer Vaccine Sales 2015-2026
2.2 Peptide Cancer Vaccine Market Size by Region: 2020 Versus 2026
2.3 Peptide Cancer Vaccine Sales by Region (2015-2026)
2.3.1 Global Peptide Cancer Vaccine Sales by Region: 2015-2020
2.3.2 Global Peptide Cancer Vaccine Sales Forecast by Region (2021-2026)
2.3.3 Global Peptide Cancer Vaccine Sales Market Share by Region (2015-2026)
2.4 Peptide Cancer Vaccine Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Peptide Cancer Vaccine Revenue by Region: 2015-2020
2.4.2 Global Peptide Cancer Vaccine Revenue Forecast by Region (2021-2026)
2.4.3 Global Peptide Cancer Vaccine Revenue Market Share by Region (2015-2026)
3 Global Peptide Cancer Vaccine by Manufacturers
3.1 Global Top Peptide Cancer Vaccine Manufacturers by Sales
3.1.1 Global Peptide Cancer Vaccine Sales by Manufacturer (2015-2020)
3.1.2 Global Peptide Cancer Vaccine Sales Market Share by Manufacturer (2015-2019)
3.2 Global Top Peptide Cancer Vaccine Manufacturers by Revenue
3.2.1 Global Peptide Cancer Vaccine Revenue by Manufacturer (2015-2020)
3.2.2 Global Peptide Cancer Vaccine Revenue Share by Manufacturer (2015-2020)
3.3 Global Peptide Cancer Vaccine Price by Manufacturer (2015-2020)
3.4 Competitive Landscape
3.4.1 Key Peptide Cancer Vaccine Manufacturers Covered: Ranking by Revenue
3.4.2 Global Peptide Cancer Vaccine Market Concentration Ratio (CR5 and HHI) & (2015-2020)
3.4.3 Global Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.5 Global Peptide Cancer Vaccine Manufacturing Base Distribution, Product Type
3.5.1 Peptide Cancer Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
3.5.2 Manufacturers Peptide Cancer Vaccine Product Type
3.5.3 Date of International Manufacturers Enter into Peptide Cancer Vaccine Market
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 TapImmune
4.1.1 TapImmune Corporation Information
4.1.2 TapImmune Description, Business Overview
4.1.3 TapImmune Peptide Cancer Vaccine Products Offered
4.1.4 TapImmune Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
4.1.5 TapImmune Peptide Cancer Vaccine Revenue by Product
4.1.6 TapImmune Peptide Cancer Vaccine Revenue by Application
4.1.7 TapImmune Peptide Cancer Vaccine Revenue by Geographic Area
4.1.8 TapImmune Peptide Cancer Vaccine Revenue by Sales Channel
4.1.9 TapImmune Recent Development
4.2 BrightPath Biotherapeutics
4.2.1 BrightPath Biotherapeutics Corporation Information
4.2.2 BrightPath Biotherapeutics Description, Business Overview
4.2.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Products Offered
4.2.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
4.2.5 BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue by Product
4.2.6 BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue by Application
4.2.7 BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue by Geographic Area
4.2.8 BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue by Sales Channel
4.2.9 BrightPath Biotherapeutics Recent Development
4.3 Ultimovacs
4.3.1 Ultimovacs Corporation Information
4.3.2 Ultimovacs Description, Business Overview
4.3.3 Ultimovacs Peptide Cancer Vaccine Products Offered
4.3.4 Ultimovacs Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
4.3.5 Ultimovacs Peptide Cancer Vaccine Revenue by Product
4.3.6 Ultimovacs Peptide Cancer Vaccine Revenue by Application
4.3.7 Ultimovacs Peptide Cancer Vaccine Revenue by Geographic Area
4.3.8 Ultimovacs Peptide Cancer Vaccine Revenue by Sales Channel
4.3.9 Ultimovacs Recent Development
4.4 Sellas
4.4.1 Sellas Corporation Information
4.4.2 Sellas Description, Business Overview
4.4.3 Sellas Peptide Cancer Vaccine Products Offered
4.4.4 Sellas Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
4.4.5 Sellas Peptide Cancer Vaccine Revenue by Product
4.4.6 Sellas Peptide Cancer Vaccine Revenue by Application
4.4.7 Sellas Peptide Cancer Vaccine Revenue by Geographic Area
4.4.8 Sellas Peptide Cancer Vaccine Revenue by Sales Channel
4.4.9 Sellas Recent Development
4.5 Boston Biomedical
4.5.1 Boston Biomedical Corporation Information
4.5.2 Boston Biomedical Description, Business Overview
4.5.3 Boston Biomedical Peptide Cancer Vaccine Products Offered
4.5.4 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
4.5.5 Boston Biomedical Peptide Cancer Vaccine Revenue by Product
4.5.6 Boston Biomedical Peptide Cancer Vaccine Revenue by Application
4.5.7 Boston Biomedical Peptide Cancer Vaccine Revenue by Geographic Area
4.5.8 Boston Biomedical Peptide Cancer Vaccine Revenue by Sales Channel
4.5.9 Boston Biomedical Recent Development
4.6 Imugene
4.6.1 Imugene Corporation Information
4.6.2 Imugene Description, Business Overview
4.6.3 Imugene Peptide Cancer Vaccine Products Offered
4.6.4 Imugene Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
4.6.5 Imugene Peptide Cancer Vaccine Revenue by Product
4.6.6 Imugene Peptide Cancer Vaccine Revenue by Application
4.6.7 Imugene Peptide Cancer Vaccine Revenue by Geographic Area
4.6.8 Imugene Recent Development
4.7 VAXON Biotech
4.7.1 VAXON Biotech Corporation Information
4.7.2 VAXON Biotech Description, Business Overview
4.7.3 VAXON Biotech Peptide Cancer Vaccine Products Offered
4.7.4 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
4.7.5 VAXON Biotech Peptide Cancer Vaccine Revenue by Product
4.7.6 VAXON Biotech Peptide Cancer Vaccine Revenue by Application
4.7.7 VAXON Biotech Peptide Cancer Vaccine Revenue by Geographic Area
4.7.8 VAXON Biotech Recent Development
4.8 Generex Biotechnology
4.8.1 Generex Biotechnology Corporation Information
4.8.2 Generex Biotechnology Description, Business Overview
4.8.3 Generex Biotechnology Peptide Cancer Vaccine Products Offered
4.8.4 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
4.8.5 Generex Biotechnology Peptide Cancer Vaccine Revenue by Product
4.8.6 Generex Biotechnology Peptide Cancer Vaccine Revenue by Application
4.8.7 Generex Biotechnology Peptide Cancer Vaccine Revenue by Geographic Area
4.8.8 Generex Biotechnology Recent Development
4.9 OncoTherapy Science
4.9.1 OncoTherapy Science Corporation Information
4.9.2 OncoTherapy Science Description, Business Overview
4.9.3 OncoTherapy Science Peptide Cancer Vaccine Products Offered
4.9.4 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
4.9.5 OncoTherapy Science Peptide Cancer Vaccine Revenue by Product
4.9.6 OncoTherapy Science Peptide Cancer Vaccine Revenue by Application
4.9.7 OncoTherapy Science Peptide Cancer Vaccine Revenue by Geographic Area
4.9.8 OncoTherapy Science Recent Development
4.10 Immatics
4.10.1 Immatics Corporation Information
4.10.2 Immatics Description, Business Overview
4.10.3 Immatics Peptide Cancer Vaccine Products Offered
4.10.4 Immatics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
4.10.5 Immatics Peptide Cancer Vaccine Revenue by Product
4.10.6 Immatics Peptide Cancer Vaccine Revenue by Application
4.10.7 Immatics Peptide Cancer Vaccine Revenue by Geographic Area
4.10.8 Immatics Recent Development
4.11 ISA Pharmaceuticals
4.11.1 ISA Pharmaceuticals Corporation Information
4.11.2 ISA Pharmaceuticals Description, Business Overview
4.11.3 ISA Pharmaceuticals Peptide Cancer Vaccine Products Offered
4.11.4 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
4.11.5 ISA Pharmaceuticals Peptide Cancer Vaccine Revenue by Product
4.11.6 ISA Pharmaceuticals Peptide Cancer Vaccine Revenue by Application
4.11.7 ISA Pharmaceuticals Peptide Cancer Vaccine Revenue by Geographic Area
4.11.8 ISA Pharmaceuticals Recent Development
5 Breakdown Data by Type
5.1 Global Peptide Cancer Vaccine Sales by Type (2015-2026)
5.1.1 Global Peptide Cancer Vaccine Sales by Type (2015-2020)
5.1.2 Global Peptide Cancer Vaccine Sales Forecast by Type (2021-2026)
5.1.3 Global Peptide Cancer Vaccine Sales Market Share by Type (2015-2026)
5.2 Global Peptide Cancer Vaccine Revenue Forecast by Type (2015-2026)
5.2.1 Global Peptide Cancer Vaccine Revenue by Type (2015-2020)
5.2.2 Global Peptide Cancer Vaccine Revenue Forecast by Type (2021-2026)
5.2.3 Global Peptide Cancer Vaccine Revenue Market Share by Type (2015-2026)
5.3 Peptide Cancer Vaccine Average Selling Price (ASP) by Type (2015-2026)
6 Breakdown Data by Application
6.1 Global Peptide Cancer Vaccine Sales by Application (2015-2026)
6.1.1 Global Peptide Cancer Vaccine Sales by Application (2015-2020)
6.1.2 Global Peptide Cancer Vaccine Sales Forecast by Application (2021-2026)
6.1.3 Global Peptide Cancer Vaccine Sales Market Share by Application (2015-2026)
6.2 Global Peptide Cancer Vaccine Revenue Forecast by Application (2015-2026)
6.2.1 Global Peptide Cancer Vaccine Revenue by Application (2015-2020)
6.2.2 Global Peptide Cancer Vaccine Revenue Forecast by Application (2021-2026)
6.2.3 Global Peptide Cancer Vaccine Revenue Market Share by Application (2015-2026)
6.3 Peptide Cancer Vaccine Average Selling Price (ASP) by Application (2015-2026)
7 North America
7.1 North America Peptide Cancer Vaccine Market Size YoY Growth 2015-2026
7.2 North America Peptide Cancer Vaccine Market Facts & Figures by Country
7.2.1 North America Peptide Cancer Vaccine Sales by Country (2015-2026)
7.2.2 North America Peptide Cancer Vaccine Revenue by Country (2015-2026)
7.3 North America Peptide Cancer Vaccine Sales by Type
7.4 North America Peptide Cancer Vaccine Sales by Application
8 Asia-Pacific
8.1 Asia-Pacific Peptide Cancer Vaccine Market Size YoY Growth 2015-2026
8.2 Asia-Pacific Peptide Cancer Vaccine Market Facts & Figures by Region
8.2.1 Asia-Pacific Peptide Cancer Vaccine Sales by Region (2015-2026)
8.2.2 Asia-Pacific Peptide Cancer Vaccine Revenue by Region (2015-2026)
8.3 Asia-Pacific Peptide Cancer Vaccine Sales by Type
8.4 Asia-Pacific Peptide Cancer Vaccine Sales by Application
9 Europe
9.1 Europe Peptide Cancer Vaccine Market Size YoY Growth 2015-2026
9.2 Europe Peptide Cancer Vaccine Market Facts & Figures by Country
9.2.1 Europe Peptide Cancer Vaccine Sales by Country (2015-2026)
9.2.2 Europe Peptide Cancer Vaccine Revenue by Country (2015-2026)
9.3 Europe Peptide Cancer Vaccine Sales by Type
9.4 Europe Peptide Cancer Vaccine Sales by Application
10 Latin America
10.1 Latin America Peptide Cancer Vaccine Market Size YoY Growth 2015-2026
10.2 Latin America Peptide Cancer Vaccine Market Facts & Figures by Country
10.2.1 Latin America Peptide Cancer Vaccine Sales by Country (2015-2026)
10.2.2 Latin America Peptide Cancer Vaccine Revenue by Country (2015-2026)
10.3 Latin America Peptide Cancer Vaccine Sales by Type
10.4 Latin America Peptide Cancer Vaccine Sales by Application
11 Middle East and Africa
11.1 Middle East and Africa Peptide Cancer Vaccine Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Peptide Cancer Vaccine Market Facts & Figures by Country
11.2.1 Middle East and Africa Peptide Cancer Vaccine Sales by Country (2015-2026)
11.2.2 Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2015-2026)
11.3 Middle East and Africa Peptide Cancer Vaccine Sales by Type
11.4 Middle East and Africa Peptide Cancer Vaccine Sales by Application
12 Supply Chain and Sales Channel Analysis
12.1 Peptide Cancer Vaccine Supply Chain Analysis
12.2 Peptide Cancer Vaccine Key Raw Materials and Upstream Suppliers
12.3 Peptide Cancer Vaccine Clients Analysis
12.4 Peptide Cancer Vaccine Sales Channel and Sales Model Analysis
12.4.1 Peptide Cancer Vaccine Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Peptide Cancer Vaccine Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Peptide Cancer Vaccine Distributors
13 Market Dynamics
13.1 Peptide Cancer Vaccine Market Drivers
13.2 Peptide Cancer Vaccine Market Opportunities
13.3 Peptide Cancer Vaccine Market Challenges
13.4 Peptide Cancer Vaccine Market Restraints
13.5 Porter's Five Forces Analysis
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of TablesTable 1. Global Peptide Cancer Vaccine Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 2. Major Manufacturers of Type I
Table 3. Major Manufacturers of Type II
Table 4. Global Peptide Cancer Vaccine Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 5. Global Peptide Cancer Vaccine Market Size by Region (US$ Million): 2020 VS 2026
Table 6. Global Peptide Cancer Vaccine Sales by Region (2015-2020) & (K Doses)
Table 7. Global Peptide Cancer Vaccine Sales Forecast by Region (2021-2026) & (K Doses)
Table 8. Global Peptide Cancer Vaccine Revenue by Region (2015-2020) & (US$ Million)
Table 9. Global Peptide Cancer Vaccine Revenue Forecast by Region (2021-2026) & (US$ Million)
Table 10. Global Peptide Cancer Vaccine Sales by Manufacturer (2015-2020) & (K Doses)
Table 11. Global Peptide Cancer Vaccine Sales Share by Manufacturer (2015-2020)
Table 12. Peptide Cancer Vaccine Revenue by Manufacturer (2015-2020) & (US$ Million)
Table 13. Peptide Cancer Vaccine Revenue Share by Manufacturer (2015-2020)
Table 14. Key Manufacturers Peptide Cancer Vaccine Price (2015-2020) & (USD/Dose)
Table 15. Ranking of Global Top Peptide Cancer Vaccine Manufacturers by Revenue (US$ Million) in 2019
Table 16. Global Peptide Cancer Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI) & (2015-2020)
Table 17. Global Peptide Cancer Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Peptide Cancer Vaccine as of 2019)
Table 18. Peptide Cancer Vaccine Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers Peptide Cancer Vaccine Product Type
Table 20. Date of International Manufacturers Enter into Peptide Cancer Vaccine Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. TapImmune Corporation Information
Table 23. TapImmune Description and Business Overview
Table 24. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 25. TapImmune Peptide Cancer Vaccine Product
Table 26. TapImmune Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 27. TapImmune Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 28. TapImmune Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 29. TapImmune Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Sales Channel
Table 30. TapImmune Recent Development
Table 31. BrightPath Biotherapeutics Corporation Information
Table 32. BrightPath Biotherapeutics Description and Business Overview
Table 33. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 34. BrightPath Biotherapeutics Peptide Cancer Vaccine Product
Table 35. BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 36. BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 37. BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 38. BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Sales Channel
Table 39. BrightPath Biotherapeutics Recent Development
Table 40. Ultimovacs Corporation Information
Table 41. Ultimovacs Description and Business Overview
Table 42. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 43. Ultimovacs Peptide Cancer Vaccine Product
Table 44. Ultimovacs Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 45. Ultimovacs Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 46. Ultimovacs Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 47. Ultimovacs Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Sales Channel
Table 48. Ultimovacs Recent Development
Table 49. Sellas Corporation Information
Table 50. Sellas Description and Business Overview
Table 51. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 52. Sellas Peptide Cancer Vaccine Product
Table 53. Sellas Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 54. Sellas Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 55. Sellas Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 56. Sellas Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Sales Channel
Table 57. Sellas Recent Development
Table 58. Boston Biomedical Corporation Information
Table 59. Boston Biomedical Description and Business Overview
Table 60. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 61. Boston Biomedical Peptide Cancer Vaccine Product
Table 62. Boston Biomedical Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 63. Boston Biomedical Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 64. Boston Biomedical Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 65. Boston Biomedical Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Sales Channel
Table 66. Boston Biomedical Recent Development
Table 67. Imugene Corporation Information
Table 68. Imugene Description and Business Overview
Table 69. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 70. Imugene Peptide Cancer Vaccine Product
Table 71. Imugene Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 72. Imugene Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 73. Imugene Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 74. Imugene Recent Development
Table 75. VAXON Biotech Corporation Information
Table 76. VAXON Biotech Description and Business Overview
Table 77. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 78. VAXON Biotech Peptide Cancer Vaccine Product
Table 79. VAXON Biotech Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 80. VAXON Biotech Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 81. VAXON Biotech Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 82. VAXON Biotech Recent Development
Table 83. Generex Biotechnology Corporation Information
Table 84. Generex Biotechnology Description and Business Overview
Table 85. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 86. Generex Biotechnology Peptide Cancer Vaccine Product
Table 87. Generex Biotechnology Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 88. Generex Biotechnology Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 89. Generex Biotechnology Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 90. Generex Biotechnology Recent Development
Table 91. OncoTherapy Science Corporation Information
Table 92. OncoTherapy Science Description and Business Overview
Table 93. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 94. OncoTherapy Science Peptide Cancer Vaccine Product
Table 95. OncoTherapy Science Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 96. OncoTherapy Science Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 97. OncoTherapy Science Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 98. OncoTherapy Science Recent Development
Table 99. Immatics Corporation Information
Table 100. Immatics Description and Business Overview
Table 101. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 102. Immatics Peptide Cancer Vaccine Product
Table 103. Immatics Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 104. Immatics Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 105. Immatics Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 106. Immatics Recent Development
Table 107. ISA Pharmaceuticals Corporation Information
Table 108. ISA Pharmaceuticals Description and Business Overview
Table 109. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 110. ISA Pharmaceuticals Peptide Cancer Vaccine Product
Table 111. ISA Pharmaceuticals Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 112. ISA Pharmaceuticals Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 113. ISA Pharmaceuticals Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 114. ISA Pharmaceuticals Recent Development
Table 115. Global Peptide Cancer Vaccine Sales by Type (2015-2020) & (K Doses)
Table 116. Global Peptide Cancer Vaccine Sales Forecast by Type (2021-2026) & (K Doses)
Table 117. Global Peptide Cancer Vaccine Revenue by Type (2015-2020) & (US$ Million)
Table 118. Global Peptide Cancer Vaccine Revenue Forecast by Type (2021-2026) & (US$ Million)
Table 119. Global Peptide Cancer Vaccine Sales by Application (2015-2020) & (K Doses)
Table 120. Global Peptide Cancer Vaccine Sales Forecast by Application (2021-2026) & (K Doses)
Table 121. Global Peptide Cancer Vaccine Revenue by Application (2015-2020) & (US$ Million)
Table 122. Global Peptide Cancer Vaccine Revenue Forecast by Application (2021-2026) & (US$ Million)
Table 123. North America Peptide Cancer Vaccine Sales by Country (2015-2020) & (K Doses)
Table 124. North America Peptide Cancer Vaccine Sales by Country (2021-2026) & (K Doses)
Table 125. North America Peptide Cancer Vaccine Revenue by Country (2015-2020) & (US$ Million)
Table 126. North America Peptide Cancer Vaccine Revenue by Country (2021-2026) & (US$ Million)
Table 127. North America Peptide Cancer Vaccine Sales by Type (2015-2020) & (K Doses)
Table 128. North America Peptide Cancer Vaccine Sales by Application (2015-2020) & (K Doses)
Table 129. Asia-Pacific Peptide Cancer Vaccine Sales by Region (2015-2020) & (K Doses)
Table 130. Asia-Pacific Peptide Cancer Vaccine Sales by Region (2021-2026) & (K Doses)
Table 131. Asia-Pacific Peptide Cancer Vaccine Revenue by Region (2015-2026) & (US$ Million)
Table 132. Asia-Pacific Peptide Cancer Vaccine Revenue by Region (2021-2026) & (US$ Million)
Table 133. Asia-Pacific Peptide Cancer Vaccine Sales by Type (2015-2020) & (K Doses)
Table 134. Asia-Pacific Peptide Cancer Vaccine Sales by Application (2015-2020) & (K Doses)
Table 135. Europe Peptide Cancer Vaccine Sales by Country (2015-2020) & (K Doses)
Table 136. Europe Peptide Cancer Vaccine Sales by Country (2021-2026) & (K Doses)
Table 137. Europe Peptide Cancer Vaccine Revenue by Country (2015-2020) & (US$ Million)
Table 138. Europe Peptide Cancer Vaccine Revenue by Country (2021-2026) & (US$ Million)
Table 139. Europe Peptide Cancer Vaccine Sales by Type (2015-2020) & (K Doses)
Table 140. Europe Peptide Cancer Vaccine Sales by Application (2015-2020) & (K Doses)
Table 141. Latin America Peptide Cancer Vaccine Sales by Country (2015-2020) & (K Doses)
Table 142. Latin America Peptide Cancer Vaccine Sales by Country (2021-2026) & (K Doses)
Table 143. Latin America Peptide Cancer Vaccine Revenue by Country (2015-2020) & (US$ Million)
Table 144. Latin America Peptide Cancer Vaccine Revenue by Country (2021-2026) & (US$ Million)
Table 145. Latin America Peptide Cancer Vaccine Sales by Type (2015-2020) & (K Doses)
Table 146. Latin America Peptide Cancer Vaccine Sales by Application (2015-2020) & (K Doses)
Table 147. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2015-2020) & (K Doses)
Table 148. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2021-2026) & (K Doses)
Table 149. Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2015-2020) & (US$ Million)
Table 150. Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2021-2026) & (US$ Million)
Table 151. Middle East and Africa Peptide Cancer Vaccine Sales by Type (2015-2020) & (K Doses)
Table 152. Middle East and Africa Peptide Cancer Vaccine Sales by Application (2015-2020) & (K Doses)
Table 153. Peptide Cancer Vaccine Key Raw Materials, Industry Status and Trend
Table 154. Peptide Cancer Vaccine Key Raw Materials and Upstream Suppliers
Table 155. Peptide Cancer Vaccine Clients Status and Trend
Table 156. Peptide Cancer Vaccine Typical Clients
Table 157. Peptide Cancer Vaccine Distributors
Table 158. Key Drivers: Impact Analysis (2021-2026)
Table 159. Peptide Cancer Vaccine Market Drivers
Table 160. Peptide Cancer Vaccine Market Opportunities
Table 161. Peptide Cancer Vaccine Market Challenges
Table 162. Peptide Cancer Vaccine Market Restraints
Table 163. Peptide Cancer Vaccine Porter's Five Forces Analysis
Table 164. Research Programs/Design for This Report
Table 165. Key Data Information from Secondary Sources
Table 166. Key Data Information from Primary Sources
List of FiguresFigure 1. Peptide Cancer Vaccine Product Picture
Figure 2. Global Peptide Cancer Vaccine Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Peptide Cancer Vaccine Sales Market Share by Application in 2020 & 2026
Figure 6. Breast Cancer Examples
Figure 7. Lung Cancer Examples
Figure 8. Melanoma Examples
Figure 9. Prostate Cancer Examples
Figure 10. Others Examples
Figure 11. Peptide Cancer Vaccine Report Years Considered
Figure 12. Global Peptide Cancer Vaccine Market Size, (US$ Million), 2015 VS 2020 VS 2026
Figure 13. Global Peptide Cancer Vaccine Market Size 2015-2026 (US$ Million)
Figure 14. Global Peptide Cancer Vaccine Sales 2015-2026 (K Units)
Figure 15. Global Peptide Cancer Vaccine Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Peptide Cancer Vaccine Sales Market Share Forecast by Region (2015-2026)
Figure 17. Global Peptide Cancer Vaccine Revenue Market Share by Region (2015-2026)
Figure 18. Global Peptide Cancer Vaccine Sales Share by Manufacturer in 2019
Figure 19. Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 20. Global Peptide Cancer Vaccine Sales Market Share Forecast by Type (2015-2026)
Figure 21. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Type (2015-2026)
Figure 22. Peptide Cancer Vaccine Average Selling Price (ASP) by Type (2015-2020) & (USD/Unit)
Figure 23. Global Peptide Cancer Vaccine Sales Market Share Forecast by Application (2015-2026)
Figure 24. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Application (2015-2026)
Figure 25. Peptide Cancer Vaccine Average Selling Price (ASP) by Application (2015-2020) & (USD/Unit)
Figure 26. North America Peptide Cancer Vaccine Revenue 2015-2026 (US$ Million)
Figure 27. North America Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Figure 28. North America Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Figure 29. Asia-Pacific Peptide Cancer Vaccine Revenue 2015-2026 (US$ Million)
Figure 30. Asia-Pacific Peptide Cancer Vaccine Sales Market Share by Region (2015-2026)
Figure 31. Asia-Pacific Peptide Cancer Vaccine Revenue Market Share by Region (2015-2026)
Figure 32. Asia-Pacific Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Figure 33. Asia-Pacific Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Figure 34. Europe Peptide Cancer Vaccine Revenue Growth Rate 2015-2026 (US$ Million)
Figure 35. Europe Peptide Cancer Vaccine Sales Market Share by Country (2015-2026)
Figure 36. Europe Peptide Cancer Vaccine Revenue Market Share by Country (2015-2026)
Figure 37. Europe Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Figure 38. Europe Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Figure 39. Latin America Peptide Cancer Vaccine Revenue Growth Rate 2015-2026 (US$ Million)
Figure 40. Latin America Peptide Cancer Vaccine Sales Market Share by Country (2015-2026)
Figure 41. Latin America Peptide Cancer Vaccine Revenue Market Share by Country (2015-2020)
Figure 42. Latin America Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Figure 43. Latin America Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Figure 44. Middle East and Africa Peptide Cancer Vaccine Revenue Growth Rate 2015-2026 (US$ Million)
Figure 45. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Country (2015-2026)
Figure 46. Middle East and Africa Peptide Cancer Vaccine Revenue Market Share by Country (2015-2026)
Figure 47. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Figure 48. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Figure 49. Peptide Cancer Vaccine Supply Chain (Upstream and Downstream Market)
Figure 50. Global Production Market Share of Peptide Cancer Vaccine Raw Materials by Region in 2019
Figure 51. Peptide Cancer Vaccine Distribution Channels
Figure 52. Global Peptide Cancer Vaccine Percentage 2015-2026: Indirect Sales VS Direct Sales
Figure 53. Global Peptide Cancer Vaccine Percentage 2015-2026: Online Sales VS Offline Sales
Figure 54. Porter's Five Forces Analysis
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed